Multi-omics profiling identifies ADAM9 as a key efferocytosis driver in lung adenocarcinoma - Quiz - MDSpire

Multi-omics profiling identifies ADAM9 as a key efferocytosis driver in lung adenocarcinoma

  • By

  • Guofu Lin

  • Lanlan Lin

  • Jianming Zhao

  • Gongping Chen

  • May 25, 2026

  • 0 min

Share

Original Source(s)

Multi-omics profiling identifies ADAM9 as a key efferocytosis driver in lung adenocarcinoma

  • by Guofu Lin, Lanlan Lin, Jianming Zhao, Gongping Chen

  • May 25, 2026

Related Content

Biotech exec Jeremy Levin on the industry’s strategic turning point

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential